Biogen Valuation

Q: What is the Fair Price of BIIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BIIB (CHF222) is trading below our estimate of [[fair value]] (CHF905.42)

Is BIIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIIB (CHF222) is trading below our estimate of fair value (CHF905.42)

Significantly Below Fair Value: BIIB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIIB?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for BIIB. This is calculated by dividing BIIB's market cap by their current preferred multiple.
What is BIIB's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$28.36b

BIIB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.4x
Enterprise Value/EBITDA	12.1x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does BIIB's PE Ratio compare to its peers?

The above table shows the PE ratio for BIIB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	41.1x
LONN Lonza Group	67.9x	24.7%	CHF 38.9b
IDIA Idorsia	10x	-20.4%	CHF 287.9m
BANB Bachem Holding	48.1x	18.7%	CHF 5.5b
SFZN Siegfried Holding	38.3x	13.6%	CHF 4.9b
BIIB Biogen	24.5x	17.0%	CHF 28.4b

Price-To-Earnings vs Peers: BIIB is good value based on its Price-To-Earnings Ratio (24.5x) compared to the peer average (41.1x).

Price to Earnings Ratio vs Industry

How does BIIB's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: BIIB is good value based on its Price-To-Earnings Ratio (24.5x) compared to the European Biotechs industry average (26x).

Price to Earnings Ratio vs Fair Ratio

What is BIIB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIIB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	24.5x
Fair PE Ratio	29.3x

Price-To-Earnings vs Fair Ratio: BIIB is good value based on its Price-To-Earnings Ratio (24.5x) compared to the estimated Fair Price-To-Earnings Ratio (29.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.